Valuation: Winston Pharmaceuticals, Inc.

Market Cap 15.48M 13.87M 12.75M 11.56M 21.6M 1.47B 22.01M 152M 61.06M 773M 58.1M 56.87M 2.44B P/E 2008
-49.9x
P/E 2009 -6.46x
Enterprise Value 13.92M 12.47M 11.47M 10.39M 19.42M 1.32B 19.78M 137M 54.89M 695M 52.24M 51.13M 2.19B EV / Sales 2008
572x
EV / Sales 2009 14.4x
Free-Float
100%
Yield 2008 *
-
Yield 2009 -
1 day-70.00%
1 week+8,999,900.00%
Current month+8,999,900.00%
1 month+8,999,900.00%
3 months+8,999,900.00%
6 months+8,999,900.00%
Current year+89,900.00%
Current year 0
Extreme 1.0E-6
0.29
1 year 0
Extreme 1.0E-6
0.29
3 years 0
Extreme 1.0E-6
0.29
5 years 0
Extreme 1.0E-6
0.3
10 years 0
Extreme 1.0E-6
0.3
Manager TitleAgeSince
Chief Executive Officer 83 2010-02-18
Change 5-day change 1-year change 3-year change Capi.($)
-70.00%+8,999,900.00%+89,900.00%+8,999,900.00% 77
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average -5.12%+5.31%+9,031.92%+900,066.10% 426.19B
Weighted average by Cap. +2.01%+6.60%+50.51%+100.44%

Financials

2008 2009
Net sales 453K 405K 373K 338K 631K 42.97M 643K 4.45M 1.78M 22.6M 1.7M 1.66M 71.28M 1.39M 1.25M 1.15M 1.04M 1.95M 132M 1.98M 13.7M 5.5M 69.66M 5.23M 5.12M 220M
Net income -5.14M -4.6M -4.24M -3.84M -7.17M -488M -7.31M -50.51M -20.28M -257M -19.3M -18.89M -810M -2.66M -2.38M -2.19M -1.98M -3.7M -252M -3.77M -26.09M -10.47M -133M -9.97M -9.75M -418M
Net Debt -5.63M -5.04M -4.64M -4.2M -7.85M -534M -8M -55.28M -22.19M -281M -21.12M -20.67M -886M -1.56M -1.4M -1.29M -1.17M -2.18M -148M -2.22M -15.35M -6.16M -78.06M -5.87M -5.74M -246M
Logo Winston Pharmaceuticals, Inc.
Winston Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company discovers, develops and commercializes therapeutics for managing and alleviating pain. The Company's late stage candidates include products for the treatment of episodic cluster headache, chronic migraine headache, osteoarthritis, rheumatoid arthritis, neuropathic pain, and pain and inflammation in inflammatory bowel disease. The Company is developing Civamide, which is a transient receptor potential channels vanilloid-1 (TRPV-1) modulator in different dosage forms for several different pain indications. The Company's other products are under development for the treatment of headache and neuropathic and rheumatological pain.
Employees
9
  1. Stock Market
  2. Stocks
  3. WPHM Stock